204 related articles for article (PubMed ID: 9422361)
1. In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions.
Hoffman AF; Gerhardt GA
J Neurochem; 1998 Jan; 70(1):179-89. PubMed ID: 9422361
[TBL] [Abstract][Full Text] [Related]
2. Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices.
Hoffman AF; Lupica CR; Gerhardt GA
J Pharmacol Exp Ther; 1998 Nov; 287(2):487-96. PubMed ID: 9808671
[TBL] [Abstract][Full Text] [Related]
3. In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors.
Zahniser NR; Larson GA; Gerhardt GA
J Pharmacol Exp Ther; 1999 Apr; 289(1):266-77. PubMed ID: 10087014
[TBL] [Abstract][Full Text] [Related]
4. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
[TBL] [Abstract][Full Text] [Related]
5. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra.
Nissbrandt H; Engberg G; Pileblad E
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):16-28. PubMed ID: 1663587
[TBL] [Abstract][Full Text] [Related]
6. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
7. In vivo electrochemical studies of dopamine clearance in subregions of rat nucleus accumbens: differential properties of the core and shell.
David DJ; Zahniser NR; Hoffer BJ; Gerhardt GA
Exp Neurol; 1998 Oct; 153(2):277-86. PubMed ID: 9784287
[TBL] [Abstract][Full Text] [Related]
8. Voltage-dependency of the dopamine transporter in the rat substantia nigra.
Hoffman AF; Zahniser NR; Lupica CR; Gerhardt GA
Neurosci Lett; 1999 Jan; 260(2):105-8. PubMed ID: 10025710
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum.
Dickinson SD; Sabeti J; Larson GA; Giardina K; Rubinstein M; Kelly MA; Grandy DK; Low MJ; Gerhardt GA; Zahniser NR
J Neurochem; 1999 Jan; 72(1):148-56. PubMed ID: 9886065
[TBL] [Abstract][Full Text] [Related]
10. Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the rat.
Régo JC; Syringas M; Leblond B; Costentin J; Bonnet JJ
Br J Pharmacol; 1999 Sep; 128(1):51-60. PubMed ID: 10498834
[TBL] [Abstract][Full Text] [Related]
11. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum.
van Horne C; Hoffer BJ; Strömberg I; Gerhardt GA
J Pharmacol Exp Ther; 1992 Dec; 263(3):1285-92. PubMed ID: 1469634
[TBL] [Abstract][Full Text] [Related]
12. In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF.
Hoffman AF; van Horne CG; Eken S; Hoffer BJ; Gerhardt GA
Exp Neurol; 1997 Sep; 147(1):130-41. PubMed ID: 9294410
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivity of dopamine release and clearance to 6-hydroxydopamine lesioning in rat striatum.
Wang Y; Tang FI; Chiou AL; Wang JY
Life Sci; 1996; 59(21):1783-92. PubMed ID: 8937505
[TBL] [Abstract][Full Text] [Related]
14. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice.
Budygin EA; John CE; Mateo Y; Jones SR
J Neurosci; 2002 May; 22(10):RC222. PubMed ID: 12006604
[TBL] [Abstract][Full Text] [Related]
15. Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding.
Rothman RB; Dersch CM; Carroll FI; Ananthan S
Synapse; 2002 Mar; 43(4):268-74. PubMed ID: 11835522
[TBL] [Abstract][Full Text] [Related]
16. Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system.
Lorenc-Koci E; Antkiewicz-Michaluk L; Wardas J; Zapała M; Wierońska J
Brain Res; 2004 May; 1009(1-2):67-81. PubMed ID: 15120584
[TBL] [Abstract][Full Text] [Related]
17. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons.
Nirenberg MJ; Vaughan RA; Uhl GR; Kuhar MJ; Pickel VM
J Neurosci; 1996 Jan; 16(2):436-47. PubMed ID: 8551328
[TBL] [Abstract][Full Text] [Related]
18. Novel Ca2+ dependence and time course of somatodendritic dopamine release: substantia nigra versus striatum.
Chen BT; Rice ME
J Neurosci; 2001 Oct; 21(19):7841-7. PubMed ID: 11567075
[TBL] [Abstract][Full Text] [Related]
19. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
Chotibut T; Apple DM; Jefferis R; Salvatore MF
PLoS One; 2012; 7(12):e52322. PubMed ID: 23300642
[TBL] [Abstract][Full Text] [Related]
20. Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to 'binge' cocaine administration.
Burchett SA; Bannon MJ
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):95-102. PubMed ID: 9387868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
